Vyne Therapeutics Inc (VYNE)
Vyne Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker VYNE. The company focuses on developing treatments for chronic inflammatory and immune-mediated conditions. Its lead program is repibresib gel (VYN201), a topical small-molecule BET inhibitor designed to act locally with low systemic exposure, and it is also advancing VYN202, an oral BD2-selective BET inhibitor being evaluated in a Phase 1b trial for immune-mediated inflammatory conditions. Founded in 2003 and based in Stewartsville, New Jersey, the company adopted the Vyne Therapeutics name in September 2020 after previously operating as Menlo Therapeutics Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VYNE
|
$0.61
|
-28.0% Downside
|
Overvalued
|
$2
|
135.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-1.3x
|
1.1x
|
62.3x
|
26.942 M
|
3.355 M
|
0.0%
|
91.6%
|
-30.1
|
—
|
118.5%
|
